Diana Brainard
Directeur Général chez ALLOVIR, INC.
Fortune : 669 395 $ au 30/04/2024
Postes actifs de Diana Brainard
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ALLOVIR, INC. | Directeur/Membre du Conseil | 01/07/2020 | - |
| Directeur Général | 17/05/2021 | - | |
| Independent Dir/Board Member | 01/04/2019 | - | |
| NEKTAR THERAPEUTICS | Directeur/Membre du Conseil | 11/11/2021 | - |
| Independent Dir/Board Member | 11/11/2021 | - | |
Affinia Therapeutics, Inc.
 Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Directeur/Membre du Conseil | 08/03/2022 | - |
| Independent Dir/Board Member | 08/03/2022 | - | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | - | - |
Historique de carrière de Diana Brainard
Anciens postes connus de Diana Brainard
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/01/2015 | 01/01/2021 |
Formation de Diana Brainard
| Brown University | Undergraduate Degree |
| Tulane University School of Medicine | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 8 |
Opérationnelle
| Director/Board Member | 3 |
| Independent Dir/Board Member | 3 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
| Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| ALLOVIR, INC. | Health Technology |
| NEKTAR THERAPEUTICS | Health Technology |
| Entreprise privées | 2 |
|---|---|
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Health Technology |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
- Bourse
- Insiders
- Diana Brainard
- Expérience
